Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-10-31
2002-09-03
Gitomer, Ralph (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S053000, C514S023000, C514S075000, C536S128000
Reexamination Certificate
active
06444654
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to the isolation and use of lipopolysaccharides from eukaryotic algae. More particularly, the present invention relates to the isolation of algal lipopolysaccharides and their use to inhibit the release of TNF-alpha from macrophages and, thus, inhibit endotoxin-initiated sepsis or septic shock. Further, the present invention relates to the use of algal lipopolysaccharides to inhibit the innate immune system of insects and mammals.
Lipopolysaccharides are high molecular weight amphipathic molecules typically associated with the cell walls of gram negative enteric bacteria. The lipopolysaccharides of gram negative bacteria are known as endotoxins and have been found to be responsible for the pathogenicity of the bacteria. The primary pathogenicity of gram negative bacteria is its physiological interaction with a host to initiate sepsis or septic shock.
When a gram negative bacterium enters a host it begins to reproduce. As the bacteria reproduces, a number of the lipopolysaccharide molecules from the cell walls of the bacteria are shed from the organisms and are released into the circulatory system of the host. The discarded lipopolysaccharide molecules then interact with the host's immune system and begin a cascade of immunorelated physiological reactions. The lipopolysaccharides interact with the host macrophages. The interaction of lipopolysaccharides with the macrophages stimulates these white cells to release the cellular hormone TNF-alpha (“TNF-a”). This TNF-a hormone negatively impacts the host and produces a series of stereotypical responses including elevated temperature, blood coagulation, changes in white blood cell morphology and increased activity of the immune response. These responses become increasingly severe and ultimately manifest clinically as sepsis or septic shock.
In the United States alone there are believed to be approximately 300,000 cases of sepsis annually. About 150,000 of these cases are fatal. Infants, the elderly and the immunocompromised, such as AIDS victims, cancer patients and transplant recipients, are particularly susceptible to sepsis. There are presently no satisfactory treatments or cures for endotoxin-initiated sepsis. Because endotoxins provoke immunological dysfunction, they cannot be used directly as immunization agents. There are currently no attenuated endotoxins or endotoxin counterparts that can be used as vaccines. The prevailing medical treatment for sepsis is founded on a symptomatic approach, treating the physical discomfort associated with the illness while hoping the disease is ultimately cured by the host's immune system. Unfortunately, as the medical field currently stands, the unlucky individual who has contracted sepsis must confront the real likelihood of death.
SUMMARY OF THE INVENTION
It is therefore a primary object of the present invention to provide a method and product for the inhibition of endotoxin-related sepsis or septic shock.
More particularly, it is an object of the present invention to provide a composition and method of using the composition to inhibit the release of TNF-a from macrophages in a host that has contacted enteric lipopolysaccharides from gram negative bacteria and, thereby, inhibit sepsis.
It is a further object of the present invention to describe a method for the isolation of a compound that can be used to inhibit the release of TNF-a from macrophages in a host that has contacted lipopolysaccharides from gram negative bacteria and, thereby, inhibit sepsis.
It is a more specific object of the present invention to disclose the isolation and purification of lipopolysaccharides from eukaryotic algae which, when introduced into a host, inhibit the release of TNF-a and, thereby, inhibit the initiation and escalation of endotoxin-initiated sepsis.
It is yet another object of the present invention to provide a composition and method of using the composition to inhibit the innate immune system of insects and mammals.
It is a more specific object of the present invention to disclose the isolation and purification of lipopolysaccharides from eukaryotic algae which, when introduced into a host, inhibit nodulation and, thereby, inhibit innate immune response in insects and mammals.
To accomplish these and other related objects, the present invention relates to the isolation and purification of lipopolysaccharides from several related strains of eukaryotic algae. These lipopolysaccharides have been shown to be structurally and functionally similar to the lipopolysaccharides of gram negative bacteria. The present invention also relates to the use of these algal lipopolysaccharides to inhibit the release of TNF-a from macrophages, which has been linked with the initiation and escalation of sepsis as a result of bacterial endotoxins. Further, the present invention relates to the use of these algal lipopolysaccharides to inhibit nodulation in insects and mammals which, in turn, inhibits innate immune response to foreign objects.
REFERENCES:
patent: 4844894 (1989-07-01), Ribi
patent: 4912094 (1990-03-01), Myers et al.
patent: 4929604 (1990-05-01), Munford et al.
patent: 5013661 (1991-05-01), Munford et al.
patent: 5041427 (1991-08-01), Takagama et al.
patent: 5530113 (1996-06-01), Christ et al.
patent: 5648343 (1997-07-01), Carlson
patent: 6172220 (2001-01-01), Pardy et al.
patent: 472 467 (1992-02-01), None
patent: 2063438 (1990-09-01), None
Bruce N. Ames, “Assay of Inorganic Phosphate, Total Phosphate and Phosphatases,”Meth. Enzymol, 8:115-118.
Ben J. Applemelk et al., “Polymyxin B-Horseradish Peroxidase Conjugates as Tools in Endotoxin Research,”Anal. Biochem., 1992, 207:311-316.
J. Bader et al., “Action of Polymyxin B on Bacterial Membranes, I: Binding to the O-Antigenic Lipopolysaccharide ofSalmonella Typhimurium,” Z. Naturforsch, 1973, 28c:422-430.
Robert M. Bannatyne et al., “Inhibition of the Biologic Effects of Endotoxin on Neutrophils by Polymyxin B Sulfate,”J. Infect. Dis., vol. 136, No. 4, Oct. 1977, pp. 469-474.
Michael S. Cooperstock, “Inactivation of Endotoxin by Polymyxin B,”Antimicrob. Ag. Chemother., vol. 6, No. 4, Oct. 1974, pp. 422-425.
Michael Cooperstock et al., “Polymyxin B Inactivation of Lipopolysaccharide in Vaccines of Gram-Negative Bacteria,”Infect. Immun., vol. 33, No. 1, Jul. 1981, pp. 315-318.
Taku Fujiwara et al., “Chemical, Immunobiological and Antigenic Characterizations of Lipopolysaccharides fromBacteriodes GingivalisStrains,”J. Gen. Microbiol., vol. 136, 1990, pp. 319-326.
R.C. Goldman et al., “Electrophoretic Separation of Lipopolysaccharide Monomers Differing in Polysaccharide Length,”Methods in Enzymology, vol. 138, 1987, pp. 267-275.
A. Hoess et al., “Crystal Structure of an Endotoxin-Neutralizing Protein From the Horseshoe Crab,LimulusAnti-LPS Factor, at 1.5 Å Resolution,”The EMBO Journal, vol. 12, 1993, pp. 3351-3356.
John L. Ingraham et al., “Growth of the Bacterial Cell,”Sinauer and Associates, Inc., Sunderland, MA, 1983, pp. 1-48.
Jerry W. Jones et al., “Green Algal Infection in a Human,”Am. J. Clin Pathol., vol. 80, No. 1, Jul. 1983, pp. 102-107.
Marlene W. Karakashian, “Symbiosis in Paramecium Bursaria,”Symp. Soc. Exp. Biol., vol. 29, 1975, pp. 145-173.
Stephen J. Karakashian, “Growth of Paramecium Bursaria as Influenced by the Presence of Algal Symbionts,”Physiol. Zool., vol. 36, 1963, pp. 52-67.
Yashwant D. Karkhanis et al., “A New and Improved Microassay to Determine 2-Keto-3-deoxyoctonate in Lipopolysaccharide of Gram-Negative Bacteria,”Anal. Biochem., vol. 85, No. 2, 1978, pp. 595-601.
William A. Lynn et al., “Lipopolysaccharide Antagonists,”Immunol. Today, vol. 13, No. 7, 1992, pp. 271-276.
K.J. Mayberry-Carson et al., “Ultrastructure of Lipopolysaccharide Isolated fromThermoplasma Acidophilum,” J. Bact., vol. 121, No. 2, Feb. 1975, pp. 700-703.
Russel H. Meints et al., “Properties of the Chlorella Receptor for the Virus PBCV-1,”Virology, vol. 164, 1988, pp. 15-21.
R.H. Meints and R.L. Pardy, “Quantitative Demonstration of Cell Surface Involvement in a Plant-Animal Symbiosis: Lect
Board of Regents of University of Nebraska
Gitomer Ralph
Khare Devesh
Shook Hardy & Bacon LLP
LandOfFree
Isolated asgal lipopolysaccharides and use of same to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolated asgal lipopolysaccharides and use of same to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated asgal lipopolysaccharides and use of same to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2869208